Literature DB >> 17519831

What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?

Kadir Demir1, Filiz Akyuz, Sadakat Ozdil, Nevzat Aksoy, Sabahattin Kaymakoglu, Sule Poturoglu, Umit Akyüz, Fatih Besisik, Gungor Boztas, Zeynel Mungan, Ugur Cevikbas, Yýlmaz Cakaloglu, Atilla Okten.   

Abstract

BACKGROUND AND STUDY AIMS: Increased alanine aminotransferase (ALT) levels with negative hepatitis B virus (HBV) DNA by hybridization is a common problem in Turkey where is a mild endemic region. We aimed to evaluate the causes of elevated ALT levels in patients who are negative for hepatitis B e antigen (HBeAg) and HBV DNA (by hybridization) for at least 6 months. PATIENTS-
METHODS: Forty-nine patients were enrolled in this study. Histological changes [histological activity index (HAI), and the extent of fibrosis] were assessed according to the Knodell scoring system and steatosis were graded by Brunt's classification for NAFLD in all patients.
RESULTS: A mean age of the patients was 34.9 +/- 12.1 years (16-70). 43 (87.8%) of them were male. Mean ALT level was 95 +/- 39.7 IU/L (50- 258). Hyperglycemia (>100 mg/dL) and hyperlipidemia were found in 12 and 24 patients, respectively. Hepatic steatosis (7 patients grade 1; 5 patients grade 2; and 7 patients grade 3), ground-glass hepatocyte, chronic hepatitis, and Wilson disease were found in liver biopsy in 38.8%, 32.6%, 26.6%, 2%, respectively. Mean HAI was 6.5 +/- 3.6 (4-12) in chronic hepatitis. Seven patients (53.9%) were in stage 1 and 2 while 6 patients (46.1%) were in stage 3 and 4.
CONCLUSIONS: Nonalcoholic fatty liver disease is the most common cause of elevated ALT levels in HBeAg negative/HBV DNA negative patients. Chronic hepatitis B was found in 26.6% of these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519831

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  7 in total

Review 1.  Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.

Authors:  Yuki Haga; Tatsuo Kanda; Reina Sasaki; Masato Nakamura; Shingo Nakamoto; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

2.  Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis.

Authors:  Rui-dan Zheng; Cheng-run Xu; Li Jiang; Ai-xia Dou; Kun Zhou; Lun-gen Lu
Journal:  Int J Med Sci       Date:  2010-08-11       Impact factor: 3.738

3.  Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.

Authors:  Richard K Sterling; Wendy C King; Mandana Khalili; David E Kleiner; Amanda S Hinerman; Mark Sulkowski; Raymond T Chung; Mamta K Jain; M Auricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Dig Dis Sci       Date:  2021-02-08       Impact factor: 3.487

4.  Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection.

Authors:  Zhiqiao Zhang; Gongsui Wang; Kaifu Kang; Guobiao Wu; Peng Wang
Journal:  Sci Rep       Date:  2016-09-06       Impact factor: 4.379

5.  A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Authors:  Jing Liang; Fang Liu; Fengmei Wang; Tao Han; Li Jing; Zhe Ma; Yingtang Gao
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

6.  Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage.

Authors:  Yong-Fen Zhu; Jin Wang; Jia-Zhui Fang; Qiao Yang; Fang-Fang Lv
Journal:  Gastroenterol Res Pract       Date:  2020-04-20       Impact factor: 2.260

7.  Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection.

Authors:  Hossein Farzi; Nasser Ebrahimi Daryani; Leila Mehrnoush; Shima Salimi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-05-01       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.